Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • priya
    Member
    • Apr 2013
    • 57

    #16
    In Group A, I have 12 samples, where the first 4(embryonic time points) can be categorised into one batch , next 4 samples (day 3.5) into one batch and last 4 samples(day 5.5) into another

    For Eg: X1,X2,X3,X4,X5,X6,X7,X8,X9,X10,X11,X12

    In Group B, I have 4 samples : 2 samples (d 3.5) and another 2 (d5.5)
    Eg: S1,S2,S3,S4

    The samples S1,S3(Wildtypes) from group B, can acts as replicates to the Samples X5, X9(Wildtypes) in group A

    Comment

    • dpryan
      Devon Ryan
      • Jul 2011
      • 3478

      #17
      Be prepared, there are probably going to be a number of semantic questions back and forth.

      So, when you say, for example, that samples X1 through X4 can be categorised as a batch, you mean not only that they're from a single developmental time point but also that the library creation/sequencing/etc. was done in a single batch (separate from the other samples). Correct? Also, were all of the red colored samples processed as a single batch or only those within each group (I assume the answer will apply to the green colored samples as well)? It's too bad there's no obvious way to make tables on this forum, that'd be really helpful here!

      The next question is which conditions you want to compare. There are quite a few possible comparisons that one could make with your experimental design, it's just a question of determining which are confounded by a batch effect.

      Comment

      • priya
        Member
        • Apr 2013
        • 57

        #18
        I tried to be more careful in answering in a clear way!

        In Group A , the 12 samples were done in single batch(similar protocol followed for library creation,sequencing by same Illumina platform(paired-end) and mapping with same parameters) compared to Group B(followed mapping with same parameters as like Group A, but library preparation and Illumina sequencing(single-end) differs).

        I just colored the 12 samples (X1..X12) with 3 different colors to differentiate the timepoints(embryonic timepoints,day 3.5 and day5.5).
        The first four samples in Group A i.e X1..X4 are from different time points
        X1 <- day d0, X2- day1, X3 - day2, X4- day3
        X5 - Wt_d3.5, X6 - aa_mutant(day 3.5), X7- bb_mutant(day3.5),X8-cc_mutant(day3.5)
        X9 - Wt_d5.5, X10 - aa_mutant(day 5.5), X11- bb_mutant(day5.5),X12-cc_mutant(day5.5)

        In Group B:
        S1- Wt_d3.5, S2 - dd_mutant(day 3.5)
        S3 -Wt_d5.5, S4 - ee_mutant(day5.5)

        However, I dont want to deal with X1-X4 samples , I am interested in X5-X12 samples in group A
        and S1-S4 samples in Group B.

        I wanted to do pairwise comparisons between X5,X6,X9,X10 samples with S1-S4 samples..
        (where X5,X9 Should have similar behavior as S1,S3 in theory)

        Comment

        • dpryan
          Devon Ryan
          • Jul 2011
          • 3478

          #19
          Ah, everything is clear then. You're in a difficult spot, unfortunately. In the direct comparisons against anything from group B, you won't be able to tell the difference between real and batch effects (aside from the problem of not having replicates). Aside from just starting over, the only other recommendation I can give is to do a few pair-wise comparisons (use the "blind" method of DESeq) and then do some validations (assuming you have access to more samples at least for qPCR) so you have an idea how many candidates might be real. It may prove cheaper, faster, and less stressful to just do more sequencing.

          Comment

          • priya
            Member
            • Apr 2013
            • 57

            #20
            Originally posted by dpryan View Post
            Ah, everything is clear then. You're in a difficult spot, unfortunately. In the direct comparisons against anything from group B, you won't be able to tell the difference between real and batch effects (aside from the problem of not having replicates). Aside from just starting over, the only other recommendation I can give is to do a few pair-wise comparisons (use the "blind" method of DESeq) and then do some validations (assuming you have access to more samples at least for qPCR) so you have an idea how many candidates might be real. It may prove cheaper, faster, and less stressful to just do more sequencing.

            It means like it turns very difficult to compare different sequencing data samples done at different time points in case of no replicates. And not able to remove batch effects if the samples of analysis were not present in both groups (if i understand correctly from your points)

            By applying DESeq "blind" method I can pick some of the significant genes by performing pairwise comparison between samples based on pvalues,foldchange values and can filter the genes with some statistics?

            Comment

            • dpryan
              Devon Ryan
              • Jul 2011
              • 3478

              #21
              Yup. You're running into two problems. The first is the lack of biological replicates, which makes it impossible to accurately measure variance in each group. The second problem is that there will often be a difference between samples processed at different dates and using paired-end versus single-end reads (the DESeq vignette has a nice example of this using the pasilla dataset). You want to be able to separate biologically meaningful differences from these "batch effects", otherwise you'll end up just wasting a lot of time and resources.

              Regarding DESeq (there are similar methods with edgeR and likely other programs), you'll get p-values, but they're not very meaningful in your situation (read through the DESeq vignette, paying particular attention to the section talking about comparisons without replicates). This is a convenient way to get fold-changes and such. You're best off filtering on fold-change and average expression level. These will probably correlate with the p-value, but I really need to stress that the p-value is not otherwise meaningful in any normal sense (i.e., do not ever try to publish it).

              Comment

              • priya
                Member
                • Apr 2013
                • 57

                #22
                Originally posted by dpryan View Post
                Yup. You're running into two problems. The first is the lack of biological replicates, which makes it impossible to accurately measure variance in each group. The second problem is that there will often be a difference between samples processed at different dates and using paired-end versus single-end reads (the DESeq vignette has a nice example of this using the pasilla dataset). You want to be able to separate biologically meaningful differences from these "batch effects", otherwise you'll end up just wasting a lot of time and resources.

                Regarding DESeq (there are similar methods with edgeR and likely other programs), you'll get p-values, but they're not very meaningful in your situation (read through the DESeq vignette, paying particular attention to the section talking about comparisons without replicates). This is a convenient way to get fold-changes and such. You're best off filtering on fold-change and average expression level. These will probably correlate with the p-value, but I really need to stress that the p-value is not otherwise meaningful in any normal sense (i.e., do not ever try to publish it).
                Thank you for your time and giving me valuable suggestions, I got an idea to deal with my datas. I try to filter some of the genes from list and see if something interesting comes up.

                Comment

                Latest Articles

                Collapse

                • SEQadmin2
                  Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
                  by SEQadmin2



                  Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

                  Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
                  ...
                  10-14-2026, 09:55 AM
                • SEQadmin2
                  New Genomics Technologies Take Aim at Long-Standing Limits
                  by SEQadmin2


                  Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

                  We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
                  ...
                  09-28-2026, 10:25 AM

                ad_right_rmr

                Collapse

                News

                Collapse

                Topics Statistics Last Post
                Started by SEQadmin2, 10-22-2026, 11:13 AM
                0 responses
                23 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 10-22-2026, 10:48 AM
                0 responses
                20 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 10-15-2026, 10:52 AM
                0 responses
                36 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 10-14-2026, 05:39 AM
                0 responses
                42 views
                0 reactions
                Last Post SEQadmin2  
                Working...